Vanguard Capital Management’s Climb Bio CLYM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.3M Buy
2,375,933
+677,279
+40% +$9.44M ﹤0.01% 2225
2026
Q2
$22.2M Buy
1,698,654
+519,995
+44% +$5.37M ﹤0.01% 2388
2026
Q1
$8.07M Buy
+1,178,659
New +$6.8M ﹤0.01% 2849

Other funds holding CLYM

Vanguard Capital Management's CLYM Position: Q3 2026 in Review

Vanguard Capital Management increased its Climb Bio (CLYM) stake by 40% in Q3 2026, buying an estimated $9.44M and bringing the position to 2,375,933 shares worth $27.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2225.

Vanguard Capital Management first reported a position in CLYM in Q1 2026 and has held it in 3 quarters since. 128 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.

  • Vanguard Capital Management held 2,375,933 shares of Climb Bio worth $27.3M as of Q3 2026.
  • Vanguard Capital Management bought 677,279 Climb Bio shares in Q3 2026, an estimated $9.44M.
  • Climb Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2225 holding.
  • Vanguard Capital Management first reported a position in Climb Bio in Q1 2026 and has held it in 3 quarters since.
  • 128 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.